Table 3. Patient characteristics (a) and their influence (b) in explaining the achievement of suppression at 6 months (through separate univariable logistic regressions).

(a)
	No history of injection drug use		History of injection drug use
	Achieved suppression at 6 months since HAART initiation				P value

Factors	No (N = 188)	Yes (N = 542)	No (N = 179)	Yes (N = 254)
Sex
Male	163 (17%)	487 (51%)	129 (13%)	186 (19%)	<0.0001
Female	25 (13%)	55 (28%)	50 (25%)	68 (34%)
HAART regimen
EFV-based	70 (13%)	269 (49%)	76 (14%)	134 (24%)	0.0035
ATA/r-based	118 (19%)	273 (44%)	103 (17%)	120 (20%)
First year adherence to HAART
>95%	134 (15%)	470 (54%)	77 (9%)	197 (22%)	<0.0001
<95%	54 (19%)	72 (25%)	102 (36%)	57 (20%)
First year of HAART
2000–2004	26 (13%)	83 (41%)	39 (19%)	54 (27%)	0.0022
2005–2006	58 (16%)	162 (44%)	65 (17%)	86 (23%)
2007–2009	104 (18%)	297 (50%)	75 (13%)	114 (19%)
Age (years)	44 (38–52)	43 (36–51)	42 (35–48)	43 (37–49)	0.0805
Baseline CD4 cell count (cells/μl)	180 (80–260)	215 (130–280)	150 (90–220)	185 (120–240)	<0.0001
Baseline viral load (log₁₀ copies/ml)	5.0 (4.9–5.0)	4.9 (4.4–5.0)	5.0 (4.7–5.0)	4.9 (4.3–5.0)	<0.0001

(b)
	Influence of each Factor on the achievement of suppression at 6 months since HAART initiation – AUC (rank)
Factors	Overall	No history of IDU	History of IDU
History of injection drug use	0.584 (4)	NA	NA
Sex	0.525 (6)	0.516 (6)	0.506 (7)
HAART regimen	0.554 (5)	0.562 (4)	0.551 (4)
First year adherence to HAART	0.632 (1)	0.577 (3)	0.673 (1)
First year of HAART	0.516 (7)	0.509 (7)	0.517 (6)
Age (years)	0.504 (8)	0.534 (5)	0.537 (5)
Baseline CD4 cell count (cells/μl)	0.592 (3)	0.585 (2)	0.583 (3)
Baseline viral load (log₁₀ copies/ml)	0.627 (2)	0.662 (1)	0.592 (2)

ATA/r, atazanavir boosted with 400 mg/day or less of ritonavir; AUC, area under the receiver operating curve; EFV, efavirenz.